We are live on ! Find out more
GLUE icon

Monte Rosa Therapeutics
GLUE

129 hedge funds and large institutions have $445M invested in Monte Rosa Therapeutics in 2025 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 41 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

59% more capital invested

Capital invested by funds: $281M → $445M (+$165M)

11% more funds holding

Funds holding: 116 → 129 (+13)

3.92% less ownership

Funds ownership: 101.14% → 97.22% (-3.9%)

15% less repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 41

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

53% less call options, than puts

Call options by funds: $1.84M | Put options by funds: $3.9M

Holders
129
Holders Change
+13
Holders Change %
+11.21%
% of All Funds
1.69%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
27
Increased
35
Reduced
41
Closed
14
Calls
$1.84M
Puts
$3.9M
Net Calls
-$2.06M
Net Calls Change
-$2.51M

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$4.24M
2
SCM
Silverarc Capital Management
Massachusetts
+$3.68M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.78M
4
Marshall Wace
Marshall Wace
United Kingdom
+$2.42M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$2.16M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$16.8M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$8.94M
3
AQR Capital Management
AQR Capital Management
Connecticut
-$3M
4
Goldman Sachs
Goldman Sachs
New York
-$1.31M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
26
Renaissance Technologies
New York
$2.93M -$1.16M -219,367 -36%
Charles Schwab
27
Charles Schwab
California
$2.84M +$10.2K +1,931 +0.5%
BCM
28
Bridgeway Capital Management
Texas
$2.66M +$463K +87,450 +32%
Jane Street
29
Jane Street
New York
$2.28M +$1.63M +307,049 New
Bank of America
30
Bank of America
North Carolina
$2M -$8.06K -1,521 -0.6%
ACM
31
ADAR1 Capital Management
Texas
$1.6M +$1.14M +215,752 New
Acadian Asset Management
32
Acadian Asset Management
Massachusetts
$1.51M +$834K +157,408 +341%
Macquarie Group
33
Macquarie Group
Australia
$1.48M +$1.06M +200,000 New
Bank of New York Mellon
34
Bank of New York Mellon
New York
$1.38M +$60.7K +11,455 +7%
TD Asset Management
35
TD Asset Management
Ontario, Canada
$1.28M – – –
Two Sigma Investments
36
Two Sigma Investments
New York
$1.2M -$416K -78,456 -33%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$1.17M -$351K -66,294 -29%
JC
38
JBF Capital
Colorado
$1.1M +$787K +148,566 New
Qube Research & Technologies (QRT)
39
Qube Research & Technologies (QRT)
United Kingdom
$1.09M -$295K -55,694 -27%
GCP
40
GSA Capital Partners
United Kingdom
$989K -$796K -150,357 -53%
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$877K -$7.7K -1,453 -1%
RC
42
Rangeley Capital
Connecticut
$837K +$598K +113,000 New
N
43
Nuveen
North Carolina
$763K – – –
Goldman Sachs
44
Goldman Sachs
New York
$749K -$1.31M -247,064 -71%
Invesco
45
Invesco
Georgia
$725K +$172K +32,509 +50%
Squarepoint
46
Squarepoint
New York
$702K -$442K -83,429 -47%
Point72 Asset Management
47
Point72 Asset Management
Connecticut
$670K +$479K +90,419 New
EF
48
Empowered Funds
Pennsylvania
$648K +$463K +87,450 New
CC
49
Casdin Capital
New York
$637K – – –
Mackenzie Financial
50
Mackenzie Financial
Ontario, Canada
$575K – – –
1
2
3 4 5

GLUE Hedge Fund Activity: Q3 2025 in Review

129 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q3 2025, worth a combined $445M — up 59% from $281M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new GLUE positions and 14 closed out — a net gain of 13 holders — while 35 added to existing stakes and 41 trimmed.

The largest buyer was Vestal Point Capital, opening a new position worth an estimated $4.24M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $16.8M sold.

  • 129 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q3 2025, up from 116 in Q2 2025.
  • Funds reported $445M of Monte Rosa Therapeutics stock for Q3 2025, up 59% quarter-over-quarter.
  • 27 funds opened new Monte Rosa Therapeutics positions in Q3 2025 and 14 closed out, a net change of +13 holders.
  • The largest Monte Rosa Therapeutics buyer in Q3 2025 was Vestal Point Capital, an estimated $4.24M added.
  • The largest Monte Rosa Therapeutics seller in Q3 2025 was Avoro Capital Advisors, an estimated $16.8M sold.

Based on aggregated 13F filings for Q3 2025.